Scientists compare FluMist and flu shot immune responses in nose and lungs
NCT ID NCT07177417
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at how two FDA-approved flu vaccines—FluMist (a nasal spray) and the standard flu shot—trigger immune responses in healthy adults aged 18 to 40. Researchers will measure antibodies in the blood, nose, and lungs before and after vaccination. Some participants will also undergo a bronchoscopy to sample lung tissue. The goal is to better understand how these vaccines protect the upper and lower airways.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY YOUNG ADULTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University in Saint Louis School of Medicine Emergency Care and Research Core
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FluMist (live attenuated influenza vaccine) and Fluarix (inactivated influenza vaccine)
What this could lead to
If successful, this study could help scientists understand how flu vaccines trigger immunity in the lungs and nose, potentially leading to better vaccines.
What could go wrong
This is a small, early-stage study (30 people) focused on measuring immune markers, not on preventing flu. Results may not apply to the general population.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.